Fourier

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Semiconductor, Research, Data Analytics, Software, Science, Hardware, Quality control, Evo, Corporation, NMR, Active ingredient, Bruker, AI, Ascend, PAT, API, Safety, Magnet, Hertz, Machine learning, Multimedia, Fourier, BRKR, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
  • The new Ascend Evo 600 magnet is easier to site, has reduced installation and operational costs, and has lower Helium consumption compared to previous 600 MHz magnets.
  • In addition, Bruker expands the applications of its Fourier 80 platform, a benchtop 80 MHz Fourier Transform NMR with a high-performance permanent magnet that requires no cryogens or power.
  • Here, the Fourier 80 system gathers reaction data for AI machine learning to formulate the rules and actions to guide process optimization.

Dxcover invited to present its CREATE-2 clinical trial for the early detection of colorectal cancer and advanced adenoma at the American Association for Cancer Research Annual Meeting 2024 in San Diego CA April 10

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Colonoscopy, Algorithm, Survival, Colorectal cancer, Patient, Cancer, Quality of life, FTIR, Machine learning, Blood, Fourier, Medical imaging

The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.

Key Points: 
  • The CREATE-2 trial evaluates diagnostic accuracy for colorectal cancer and high-risk adenoma in patients undergoing a colonoscopy.
  • The prospective observational study has two recruitment pathways, one in the US (targeting 1000 patients) and one in the UK (targeting 700 patients).
  • CREATE-2 intends to validate the previous feasibility study results from CREATE-1 which showed Dxcover’s ability to achieve accurate detection of pre-cancerous lesions and stage 1 colorectal cancer.
  • Dxcover’s Multi-Omic Spectral Analysis (MOSA-Dx™) enables analysis the full complement of signals within the blood to provide early detection of cancer.

Symphony hails US Environmental Protection Agency report on pro-oxidants

Retrieved on: 
Monday, March 11, 2024
Depolymerization, TGA, FTIR, Spectroscopy, GC, Microplastics, Water, Fourier, Plastic, Environment, Ageing, PP

LONDON, March 11, 2024 /PRNewswire/ -- Symphony Environmental Technologies Plc. have commented on this important statement from the US Environmental Protection Agency (EPA). 

Key Points: 
  • Blending plastics with pro-oxidants could be a promising solution, as they accelerate photooxidation to obtain degradable materials whose final ecological and physical footprint are much smaller."
  • "In this study, two pro-oxidants, iron stearate (FeSt3) and cobalt stearate (CoSt2), were melt-blended with polypropylene (PP) at concentrations of 1 and 2 wt%.
  • After 500 h of aging plastics plates showed significant reduction in melting and re-crystallization points - indicating polymer-chain breaking, rapid depolymerization."
  • The study offers a successful approach where benign filler could significantly reduce the persistence of plastic pollution without creating undesired by-products."

Dxcover Announces Three New Clinical Trials for Brain, Colorectal and Lung Cancer Detection

Retrieved on: 
Tuesday, January 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Brain, FTIR, CREATE, Patient, Fourier, European Innovation Council, IVD, Cancer, Algorithm, Colonoscopy, Brain tumor, Disease, NHS, Machine learning, NHS Lothian, Colorectal cancer, EMBRACE, Medical imaging

Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.

Key Points: 
  • Dxcover Limited , a clinical-stage diagnostics company pioneering multi-omic spectral analysis (MOSA) for early detection of multiple cancers, today announced it is initiating three pivotal clinical trials measuring efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal and lung cancer.
  • The company has launched its EMBRACE study, a 2,200-patient trial focused on the early detection of brain cancer.
  • Dxcover® Brain Cancer is a qualitative in vitro diagnostic (IVD) test analyzing blood serum by infrared spectroscopy to detect the signals indicative of brain cancer.
  • The Dxcover Brain Cancer test has been developed over four years with clinical support from NHS Lothian.

MicroCloud Hologram develops a sports training system with a holographic brain-computer interface

Retrieved on: 
Friday, September 8, 2023
Exercise, Communication, BCI, Classification, Culture, DSP, FFT, Stroke, Microelectrode, Rehabilitation, Research, Sympathetic nervous system, DSM-IV codes, Movement, Language, SVM, Cerebral cortex, DFT, Signal, Acquisition, Patient, Machine learning, Hearing, Fourier, EEG, MEMS, Diagnosis, ICA, AR, CSP, Common, Medical imaging

Brain-computer interface is a communication technology that does not depend on people's normal peripheral nerves and muscle tissue.

Key Points: 
  • Brain-computer interface is a communication technology that does not depend on people's normal peripheral nerves and muscle tissue.
  • The motion training system of holographic brain-computer interface solves the difficult problem of exercise for patients with functional disorders, and stimulates, extracts and utilizes their active movement willingness.
  • The filtered EEG signal is then identified and matched by intelligent algorithm according to holographic data in holographic data tag library.
  • In the field of rehabilitation medicine, the motion training system of holographic brain-computer interface can effectively assist the rehabilitation training of neuromuscular patients such as stroke or spinal cord injury by controlling robotic arms and exoskeleton robots.

WiMi Developed a Real-Time Three-Dimensional Holographic Communication System

Retrieved on: 
Wednesday, September 6, 2023
Cloud, Holography, Communication, Augmented reality, Data compression, Education, Classification, WIMI, 3D, Light, Medicine, CNN, Science, Projection, Algorithm, Fourier, AR, Security printing, Computer data storage

BEIJING, Sept. 6, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it developed the real-time three-dimensional holographic communication system.

Key Points: 
  • BEIJING, Sept. 6, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it developed the real-time three-dimensional holographic communication system.
  • The core technology of the real-time 3D holographic communication system includes holographic imaging, holographic coding and holographic projection.
  • In the real-time 3D holographic communication system, the implementation of the algorithm is the key to realize the function of the system.
  • The real-time 3D holographic communication system being developed by WiMi is a communication technology with great potential, which is capable of realizing long-distance transmission and displaying real 3D images, bringing people a more immersive, intuitive and real communication experience, and promoting the development and innovation of communication technology.

WiMi Developed A Memristor-based Analog Digital Reservoir Computing System for Signal Processing

Retrieved on: 
Thursday, July 13, 2023
Cloud, Holography, Neuron, Augmented reality, Noise, Classification, WIMI, Intelligence, Internet, Fourier, Memory, AR, Satellite navigation device, Instrumentation, Electronics

BEIJING, July 13, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced the development of a digital reservoir (DR) computing system for real-time and energy-efficient signal processing.

Key Points: 
  • BEIJING, July 13, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced the development of a digital reservoir (DR) computing system for real-time and energy-efficient signal processing.
  • Unlike traditional digital reservoir technology, WiMi's system can be designed using analog circuitry to implement reservoir technology's randomly connected neuron structure.
  • In addition, the system can use digital signal processing techniques, such as fast Fourier transform and wavelet transform, to further process the output signal of the reservoir.
  • The memristor-based analog digital reservoir computing system developed by WiMi has excellent real-time performance and energy efficiency.

Onto Innovation Expands Portfolio of Process Control Solutions for High Growth Specialty Markets

Retrieved on: 
Wednesday, July 12, 2023
Software, Technology, Hardware, Semiconductor, Surjective function, OCD, DRAM, Onto Innovation, NAND, EPI, CIS, Silicon carbide, Fourier, FTIR, Element, MEMS, Growth, NYSE, Gallium nitride, Video game, Si

The two new systems complement existing Dragonfly® inspection, IVS™ overlay, and Echo™ metrology product families building on the company’s strategy to provide a portfolio of comprehensive process control tools and software that work together to solve a wide range of inherent process challenges in the specialty markets.

Key Points: 
  • The two new systems complement existing Dragonfly® inspection, IVS™ overlay, and Echo™ metrology product families building on the company’s strategy to provide a portfolio of comprehensive process control tools and software that work together to solve a wide range of inherent process challenges in the specialty markets.
  • Within the specialty markets, growth of power applications, based on Si, SiC and GaN device technologies, is fueled by the transition to electric vehicles and the rapid adoption of GaN into fast charge applications in both consumer and automotive markets.
  • Specifically, the demand for SiC and GaN power devices is seeing an annual average growth rate approaching 34% and 44% respectively, through 2027, according to Yole Group.
  • The breadth of capabilities and productivity of the Atlas S system are well suited to a broad range of specialty applications.

WiMi Developed A Single-pixel Digital Holography-based Compressive phase object classification Technology

Retrieved on: 
Monday, June 26, 2023
Cloud, Holography, Tissue, Augmented reality, AWP, Classification, WIMI, Garden, Facial recognition, Wavefield Inseis, Algorithm, Fourier, Ophthalmology, CCD, City, AR, Skin, Television, Computer data storage, Medical imaging

BEIJING, June 26, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced the development of a single-pixel digital holography-based compressive phase target classification technology.

Key Points: 
  • BEIJING, June 26, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced the development of a single-pixel digital holography-based compressive phase target classification technology.
  • The core of this target classification technology is digital holography and phase extraction.
  • The single-pixel digital holography-based compressive phase target classification technique is highly compressible compared to traditional digital holography.
  • The single-pixel digital holography-based compressive phase target classification technology has a wide range of application scenarios.

Dxcover Presents Data on Liquid Biopsy Platform for Early Colorectal Cancer Detection at 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Survival rate, DNA, AACR, CMS, CRC, Centers for Medicare & Medicaid Services, Survival, Cancer, Woman, Biomarker, Doctor of Philosophy, Medicare, Patient, Colorectal cancer, Machine learning, Fourier, FTIR, Algorithm, Diagnosis, Liquid biopsy, AA, Medical imaging

Dxcover Limited , a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today presented new data in a presentation titled “Early Detection and Molecular Markers of Prevention” on the detection of colorectal cancer (CRC) using the company’s liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida from April 14-19.

Key Points: 
  • Dxcover Limited , a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today presented new data in a presentation titled “Early Detection and Molecular Markers of Prevention” on the detection of colorectal cancer (CRC) using the company’s liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida from April 14-19.
  • Co-founder and CTO Matthew Baker, PhD, outlined data from a preclinical study evaluating the Dxcover® Cancer Liquid Biopsy platform’s capabilities to detect advanced adenomas and early cases of colorectal cancer.
  • CRC is the third most common cancer among both men and women, which would greatly benefit from earlier detection due to decreased survival rates as the cancer progresses.
  • “Early detection, and the detection of pre-cancerous adenomas, is critical to advancing lifespan for those impacted by potentially devastating diseases like colorectal cancer.